



Which Companies Faced the Most Federal Antitrust Lawsuits in FY2025

Original analysis of 1,386 records from the Federal Judicial Center, FY2024–FY2025 (Oct 2023–Sep 2025). Published October 17, 2026. <https://settlementinsight.com/research/most-sued-companies-antitrust-lawsuits>

GoodRx was the first-listed defendant in 30 new federal antitrust lawsuits in fiscal year 2025, more than any other company, just ahead of the NCAA with 29. MultiPlan (24), Blue Cross Blue Shield entities with no state plan named (19) and Google (18) follow. Out of 481 new antitrust lawsuits, the ten most-named first defendants account for 37.8%.

30

New FY2025 antitrust suits naming GoodRx first

481

New federal antitrust lawsuits in FY2025


38%

Share naming one of the top 10 defendants first



New federal antitrust lawsuits by first-listed defendant, FY2025

Top 12 of 29



Source: Settlement Insight analysis of data from the Federal Judicial Center

settlementinsight.com/research/most-sued-companies-antitrust-lawsuits · free to use with a link (CC BY 4.0)

What the FY2025 antitrust filings show

- GoodRx leads by a single case.** GoodRx was named first in 30 new lawsuits and the NCAA in 29. Counting each first-listed plaintiff only once, GoodRx still leads (28 against 25).
- The NCAA was sued in the most courts.** Lawsuits naming the NCAA first were filed in 21 different district courts; the 30 GoodRx lawsuits were spread over 8.

3. **Health care companies cluster near the top.** MultiPlan (24), Blue Cross Blue Shield (19) and Zelis Healthcare (7) are among the most-named first defendants, next to GoodRx.
4. **Last year's leader fell back.** Apple was the most-named first defendant in FY2024 with 52 new lawsuits; in FY2025 it was named first in 6.
5. **All antitrust case records fell more than new filings.** All antitrust case records fell 27.0% from FY2024 to FY2025, but new lawsuits fell only 9.4%; the difference is mostly fewer reopened and transferred cases.
6. **One court took a fifth of the cases.** The Northern District of Illinois received 98 of the 481 new antitrust lawsuits (20.4%).

How we measured

Data come from the Federal Judicial Center's Integrated Database (IDB), civil cumulative file covering cases terminated through June 30, 2026 and cases pending on that date, as imported into our database on October 10, 2026. Each record is one filing of a civil case in a U.S. district court, identified by circuit, district, office and docket number; a reopened case receives an additional record under the same number.

We selected nature-of-suit code 410 (Antitrust) and assigned cases to federal fiscal years by the actual filing date (FJC field FILEDATE, not the tape year): FY2025 runs from October 1, 2024 to September 30, 2025, FY2024 from October 1, 2023 to September 30, 2024. For the rankings we kept only origin codes 1 (original proceeding), 2 (removed from state court) and 13 (MDL originating in the district) and counted distinct case numbers, which leaves 481 new lawsuits in FY2025 and 531 in FY2024.

Each lawsuit is assigned to its first-listed defendant as recorded by the courts (the field is cut off at 30 characters). Spelling variants and entities sharing the same name stem are merged (for example GoodRx, Inc. and GoodRx Holdings, Inc.; CVS Caremark and CVS Health). Differently named affiliates are not merged. Every name variant behind each row is listed in the CSV.

For the check on parallel filings, we counted distinct first-listed plaintiffs among each company's new FY2025 lawsuits. Plaintiff names were compared after removing "et al." and punctuation; identical names count once even when only a surname is recorded, so plaintiffs sharing a surname in different districts count as one. A name cut off at the 30-character field limit counts as the same plaintiff as a longer name in the same group that begins with it (for example "Philadelphia Associatio" and "Philadelphia Association of Re"). This gives 28 distinct plaintiffs for GoodRx and 25 for the NCAA; plaintiff names are not published.

To check the data, we counted all antitrust records regardless of origin and compared them with Table C-2 of the judiciary's Judicial Business report: 585 against 591 published for FY2025 (a difference of 1.0%) and 801 against 800 for FY2024 (0.1%). The FJC notes that counts based on actual filing dates, as used here, may differ slightly from the published tables, which use a separate filing date for statistical reporting.

Checked against published figures

- Antitrust civil cases commenced in U.S. district courts, FY2025 (12 months ending Sep 30, 2025): published 591, our count 585 (1.02% apart). [Table C-2. U.S. District Courts—Civil Cases Commenced, by Basis of Jurisdiction and Nature of Suit \(Judicial Business 2025\)](#).

- Antitrust civil cases commenced in U.S. district courts, FY2024 (12 months ending Sep 30, 2024): published 800, our count 801 (0.13% apart). [Table C-2. U.S. District Courts—Civil Cases Commenced, by Basis of Jurisdiction and Nature of Suit \(Judicial Business 2025\)](#).

Limitations

- Only the first-listed defendant is counted. A lawsuit against several companies counts once, for the company named first: the GoodRx cases, for example, also name pharmacy benefit managers such as CVS Caremark and Express Scripts, which are not credited here.
- A lawsuit is not a separate dispute. Antitrust claims are often filed as many parallel class actions over the same alleged conduct, and some cases are dismissed and refiled elsewhere. The counts measure filings, not distinct disputes, and say nothing about whether any claim succeeded.
- Names are grouped by hand from truncated text. Blue Cross Blue Shield entries without a state plan name may refer to the national association or to several plans and are shown as one row; 3 new FY2025 lawsuits name a defendant cut off too early to identify (for example "National Association of") and are not attributed.
- Counts are not adjusted for company size, market share or number of customers.
- The FJC file is updated as courts report and correct cases; later releases may change FY2025 counts slightly, mainly through late-reported cases and corrected origin codes.

Data files

- [Most-named first defendants in new federal antitrust lawsuits, FY2024](#) (CSV, 24 rows)
- [Most-named first defendants in new federal antitrust lawsuits, FY2025](#) (CSV, 29 rows)
- [New federal antitrust lawsuits by district court, FY2025](#) (CSV, 66 rows)
- [Federal antitrust case records by how the case arrived in the district, FY2025 and FY2024](#) (CSV, 8 rows)

How to cite

Goldberg, L. (2026). Federal Antitrust Lawsuits by First-Listed Defendant — New Filings in U.S. District Courts (FY2024–FY2025) [Data set]. Settlement Insight. <https://settlementinsight.com/research/most-sued-companies-antitrust-lawsuits>

Free to reuse with attribution under CC BY 4.0. Please link to <https://settlementinsight.com/research/most-sued-companies-antitrust-lawsuits> as the source.